Ahmed H. Eldib
Research Subjects
Research Interests
Ahmed H. Eldib has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Shaheen Tomah
Altimmune, Inc, Gaithersburg, MD, USA
8 shared publications Osama Hamdy
Boston, MA, Cambridge, MA
5 shared publicationsMhd Wael Tasabehji
Research Division, Joslin Diabetes Center, Boston, MA, USA
4 shared publications- Osama Hamdy
Joslin Diabetes Center, Boston, MA
4 shared publications Sahar Ashrafzadeh
Boston, MA, Worcester, MA
3 shared publicationsAdham Mottalib
Boston, MA, Worcester, MA
2 shared publications
Latest Publications
- 1 August 2020
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 112 (2) , 293-302
Effect of dairy consumption and its fat content on glycemic control and cardiovascular disease risk factors in patients with type 2 diabetes: a randomized controlled study
Dietary Guidelines for Americans recommend the consumption of 3 servings/d of low-fat/nonfat dairy. The effects of higher dairy consumption and its fat content are unknown in patients with type 2 diabetes. Evaluate the impact of higher consumption of high- compared with low-fat dairy on glycated hemoglobin (HbA1c), body weight, and cardiovascular disease risk factors in patients with type 2 diabetes. We enrolled 111 subjects with type 2 diabetes (aged 58.5 ± 8.9 y, 47% females, diabetes duration 13.2 ± 8.3 y, HbA1c 8.09 ± 0.96%) who consumed <3 servings of dairy/d. We randomly assigned them into 3 groups: control group maintained baseline dairy intake, low-fat (LF) group incorporated ≥3 servings/d of LF dairy, and the high-fat (HF) group incorporated ≥3 servings/d of HF dairy. We evaluated HbA1c, body weight, BMI, body composition parameters, blood pressure (BP), lipid parameters, homeostatic model assessment of insulin resistance (HOMA-IR), and total energy and macronutrient intake at baseline, and after 12 and 24 wk. At 24 wk, percent energy from saturated fat increased from baseline in the HF group by 3.6%, (95% CI: 2.2, 5.1) and decreased in the LF group by -1.9% (95% CI: -3.3, -0.4). The LF group increased their percent energy from protein by 4.5% (95% CI: 2.6, 6.4), whereas the HF group decreased their percent energy from carbohydrates by -3.4% (95% CI: -0.2, -6.7). There were no differences in the mean changes in HbA1c, body weight, BMI, body composition or lipid parameters, or BP between the 3 groups at 24 wk. In patients with type 2 diabetes, increased dairy consumption to ≥3 servings/d compared with <3 servings/d, irrespective of its fat content, while maintaining energy intake has no effect on HbA1c, body weight, body composition, lipid profile, or BP. This trial was registered at clinicaltrials.gov as NCT02895867.
- 1 August 2020
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 112 (2) , 293-302
Effect of dairy consumption and its fat content on glycemic control and cardiovascular disease risk factors in patients with type 2 diabetes: a randomized controlled study
Dietary Guidelines for Americans recommend the consumption of 3 servings/d of low-fat/nonfat dairy. The effects of higher dairy consumption and its fat content are unknown in patients with type 2 diabetes. Evaluate the impact of higher consumption of high- compared with low-fat dairy on glycated hemoglobin (HbA1c), body weight, and cardiovascular disease risk factors in patients with type 2 diabetes. We enrolled 111 subjects with type 2 diabetes (aged 58.5 ± 8.9 y, 47% females, diabetes duration 13.2 ± 8.3 y, HbA1c 8.09 ± 0.96%) who consumed <3 servings of dairy/d. We randomly assigned them into 3 groups: control group maintained baseline dairy intake, low-fat (LF) group incorporated ≥3 servings/d of LF dairy, and the high-fat (HF) group incorporated ≥3 servings/d of HF dairy. We evaluated HbA1c, body weight, BMI, body composition parameters, blood pressure (BP), lipid parameters, homeostatic model assessment of insulin resistance (HOMA-IR), and total energy and macronutrient intake at baseline, and after 12 and 24 wk. At 24 wk, percent energy from saturated fat increased from baseline in the HF group by 3.6%, (95% CI: 2.2, 5.1) and decreased in the LF group by -1.9% (95% CI: -3.3, -0.4). The LF group increased their percent energy from protein by 4.5% (95% CI: 2.6, 6.4), whereas the HF group decreased their percent energy from carbohydrates by -3.4% (95% CI: -0.2, -6.7). There were no differences in the mean changes in HbA1c, body weight, BMI, body composition or lipid parameters, or BP between the 3 groups at 24 wk. In patients with type 2 diabetes, increased dairy consumption to ≥3 servings/d compared with <3 servings/d, irrespective of its fat content, while maintaining energy intake has no effect on HbA1c, body weight, body composition, lipid profile, or BP. This trial was registered at clinicaltrials.gov as NCT02895867.
- Open Access
Dairy Consumption and Cardiometabolic Risk Factors in Patients with Type 2 Diabetes and Overweight or Obesity during Intensive Multidisciplinary Weight Management: A Prospective Observational Study
Dairy products are integral parts of healthy diets; however, their association with cardiometabolic (CM) health among patients with type 2 diabetes (T2D) undergoing weight management is debated. We examined the relationship between dairy consumption and CM biomarkers in 45 subjects with T2D and obesity (mean age 56 ± 9 yrs, 40% female) enrolled in a 12-week intensive multidisciplinary weight management (IMWM) program. After the IMWM program (intervention phase), subjects were followed for 12 weeks (maintenance phase). We stratified subjects based on initial average dairy consumption into infrequent (IFR), less-frequent (LFR), and frequent (FR) consumers. Outcomes were assessed at baseline, 12, and 24 weeks. There were no differences between tertiles at baseline except for higher total energy intake among FR compared with IFR. HbA1c changes showed no association with dairy consumption at 12 or 24 weeks. FR Females achieved greater weight loss at 12 weeks compared with IFR peers (−4.5 kg; 95%CI: −5.5, −3.5). There was a trend towards lower HDL-C with increasing dairy consumption during the intervention phase. In subjects with T2D and overweight or obesity, dairy consumption during weight management is not associated with HbA1c changes but with lower HDL-C and with higher magnitude of weight loss among females.
Open AccessDairy Consumption and Cardiometabolic Risk Factors in Patients with Type 2 Diabetes and Overweight or Obesity during Intensive Multidisciplinary Weight Management: A Prospective Observational Study
Dairy products are integral parts of healthy diets; however, their association with cardiometabolic (CM) health among patients with type 2 diabetes (T2D) undergoing weight management is debated. We examined the relationship between dairy consumption and CM biomarkers in 45 subjects with T2D and obesity (mean age 56 ± 9 yrs, 40% female) enrolled in a 12-week intensive multidisciplinary weight management (IMWM) program. After the IMWM program (intervention phase), subjects were followed for 12 weeks (maintenance phase). We stratified subjects based on initial average dairy consumption into infrequent (IFR), less-frequent (LFR), and frequent (FR) consumers. Outcomes were assessed at baseline, 12, and 24 weeks. There were no differences between tertiles at baseline except for higher total energy intake among FR compared with IFR. HbA1c changes showed no association with dairy consumption at 12 or 24 weeks. FR Females achieved greater weight loss at 12 weeks compared with IFR peers (−4.5 kg; 95%CI: −5.5, −3.5). There was a trend towards lower HDL-C with increasing dairy consumption during the intervention phase. In subjects with T2D and overweight or obesity, dairy consumption during weight management is not associated with HbA1c changes but with lower HDL-C and with higher magnitude of weight loss among females.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
976-P: Evaluation of Hybrid Closed-Loop Insulin Delivery System for Patients with Type 1 Diabetes in Real-World Clinical Practice: A One-Year Qualitative Observational Study
The MiniMed™ 670G (670G) is the first FDA approved hybrid closed-loop insulin delivery system for patients with type 1 diabetes (T1D). In Auto Mode, the integrated continuous glucose monitor (CGM) captures glucose values every five minutes and, via a built-in algorithm, the 670G system automatically adjusts basal insulin delivery targeting a glucose value of 120 mg/dL. Impact of the use of 670G system on patient reported outcomes in people with T1D are limited. Data over one year of use in real world-clinical practice were collected. We evaluated 53 patients with T1D (mean age 46.8±11.8 years, 62% females, body weight 82.5±17.6 kg, BMI 28.7±5.5, HbA1c 7.6±0.8%) who started 670G at the Joslin Clinic between December 2017 and December 2019. Data were collected at baseline and after 12 months. We assessed SROs by administering surveys: 36 Item Short-Form Health Survey (SF 36), Pittsburgh Sleep Quality Index (PSQI), and hypoglycemia fear survey/worry scale (HFS_W). We also measured HbA1c, % time-in-range at baseline and 12 months, and % time in auto mode (TiAM) for the two weeks preceding the final study visit. At 12 months, A1C decreased by 0.3±0.1% from baseline (pp=0.015) with no correlation between either of them and %TiAM (p=0.3, p=0.2 respectively). Physical functioning increased by 47.5% from baseline (pp=0.017). At 12 months, average %TiAM was 60.4±33.7% and was not associated with clinical outcomes or SROs. We conclude that use of 670G for a year in real-world clinical practice was associated with significant improvement in A1C, % time-in-range, physical functioning and hypoglycemia fear. Neither of these improvements at 12 months was related to %TiAM. Disclosure A.H. Eldib: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. S.E. Dhaver: None. H. Gardner: None. M. Tasabehji: None. M. Albadri: None. A. Atakov-Castillo: None. E. Toschi: None. O. Hamdy: Consultant; Self; Abbott, AstraZeneca, Merck & Co., Inc., Sanofi-Aventis. Research Support; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Healthimation, LLC.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
976-P: Evaluation of Hybrid Closed-Loop Insulin Delivery System for Patients with Type 1 Diabetes in Real-World Clinical Practice: A One-Year Qualitative Observational Study
The MiniMed™ 670G (670G) is the first FDA approved hybrid closed-loop insulin delivery system for patients with type 1 diabetes (T1D). In Auto Mode, the integrated continuous glucose monitor (CGM) captures glucose values every five minutes and, via a built-in algorithm, the 670G system automatically adjusts basal insulin delivery targeting a glucose value of 120 mg/dL. Impact of the use of 670G system on patient reported outcomes in people with T1D are limited. Data over one year of use in real world-clinical practice were collected. We evaluated 53 patients with T1D (mean age 46.8±11.8 years, 62% females, body weight 82.5±17.6 kg, BMI 28.7±5.5, HbA1c 7.6±0.8%) who started 670G at the Joslin Clinic between December 2017 and December 2019. Data were collected at baseline and after 12 months. We assessed SROs by administering surveys: 36 Item Short-Form Health Survey (SF 36), Pittsburgh Sleep Quality Index (PSQI), and hypoglycemia fear survey/worry scale (HFS_W). We also measured HbA1c, % time-in-range at baseline and 12 months, and % time in auto mode (TiAM) for the two weeks preceding the final study visit. At 12 months, A1C decreased by 0.3±0.1% from baseline (pp=0.015) with no correlation between either of them and %TiAM (p=0.3, p=0.2 respectively). Physical functioning increased by 47.5% from baseline (pp=0.017). At 12 months, average %TiAM was 60.4±33.7% and was not associated with clinical outcomes or SROs. We conclude that use of 670G for a year in real-world clinical practice was associated with significant improvement in A1C, % time-in-range, physical functioning and hypoglycemia fear. Neither of these improvements at 12 months was related to %TiAM. Disclosure A.H. Eldib: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. S.E. Dhaver: None. H. Gardner: None. M. Tasabehji: None. M. Albadri: None. A. Atakov-Castillo: None. E. Toschi: None. O. Hamdy: Consultant; Self; Abbott, AstraZeneca, Merck & Co., Inc., Sanofi-Aventis. Research Support; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Healthimation, LLC.
- Open Access
- 24 September 2019
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 9 (1) , 1-6
Effect of diabetes-specific nutrition formulas on satiety and hunger hormones in patients with type 2 diabetes
Objectives: Diabetes-specific nutritional formulas (DSNFs) are frequently used by patients with type 2 diabetes (T2D) as part of nutrition therapy to improve glycemic control and reduce body weight. However, their effects on hunger and satiety hormones when compared to an isocaloric standardized breakfast are not fully understood. This study aims to evaluate the postprandial effects of two DSNFs—Glucerna (GL) and Ultra Glucose Control (UGC)—versus oatmeal on selected satiety and hunger hormones. Method: After an overnight fast, 22 patients with T2D (mean age 62.3 ± 6.8 years, A1C 6.8 ± 0.7%, body weight 97.4 ± 21.3 kg, and BMI 33.2 ± 5.9 kg/m²) were given 200 kcal of each meal on three separate days. Blood samples for amylin, cholecystokinin (CCK), ghrelin, glucagon, leptin, and peptide-YY (PYY) were collected at baseline and 30, 60, 90, 120, 180, and 240 min after the start of each meal. Incremental area under the curve (iAUC0-240) for each hormone was calculated. Results: iAUC0-240 for glucagon and PYY were significantly higher after GL and UGC than after oatmeal (p < 0.001 for both). No difference was observed between the three meals on postprandial amylin, CCK, ghrelin, and leptin hormones. Conclusions: Intake of DSNFs significantly increases secretion of PYY and glucagon, two important satiety hormones. While subjective satiety was not directly evaluated, the increased effect on satiety hormones may partially explain the mechanism of body weight loss associated with DSNF use.
- 24 September 2019
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 9 (1) , 1-6
Open AccessEffect of diabetes-specific nutrition formulas on satiety and hunger hormones in patients with type 2 diabetes
Objectives: Diabetes-specific nutritional formulas (DSNFs) are frequently used by patients with type 2 diabetes (T2D) as part of nutrition therapy to improve glycemic control and reduce body weight. However, their effects on hunger and satiety hormones when compared to an isocaloric standardized breakfast are not fully understood. This study aims to evaluate the postprandial effects of two DSNFs—Glucerna (GL) and Ultra Glucose Control (UGC)—versus oatmeal on selected satiety and hunger hormones. Method: After an overnight fast, 22 patients with T2D (mean age 62.3 ± 6.8 years, A1C 6.8 ± 0.7%, body weight 97.4 ± 21.3 kg, and BMI 33.2 ± 5.9 kg/m²) were given 200 kcal of each meal on three separate days. Blood samples for amylin, cholecystokinin (CCK), ghrelin, glucagon, leptin, and peptide-YY (PYY) were collected at baseline and 30, 60, 90, 120, 180, and 240 min after the start of each meal. Incremental area under the curve (iAUC0-240) for each hormone was calculated. Results: iAUC0-240 for glucagon and PYY were significantly higher after GL and UGC than after oatmeal (p < 0.001 for both). No difference was observed between the three meals on postprandial amylin, CCK, ghrelin, and leptin hormones. Conclusions: Intake of DSNFs significantly increases secretion of PYY and glucagon, two important satiety hormones. While subjective satiety was not directly evaluated, the increased effect on satiety hormones may partially explain the mechanism of body weight loss associated with DSNF use.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
742-P: Magnitude of A1C Improvement in Relation to Weight Loss after Intensive Lifestyle Intervention in Real-World Diabetes Practice: Thirteen Years of Observation
The effect of intensive lifestyle intervention (ILI) on A1C in real-world clinical practice is inconsistent and is frequently underestimated. It is also presumed that the magnitude of A1C improvement is solely dependent on the amount of weight loss. In this study we report the magnitude of A1C change in a large cohort of patients with diabetes who underwent ILI over 13 years in relation to their baseline A1C and the amount of weight loss. We evaluated 590 diabetic patients (age 52.5±11 years, 58.6% females, A1C 7.7±1.4%, weight 105.54±18.6 Kg, BMI 36.7±5.1 Kg/m2, diabetes duration 10.9±9.8 years, 83.7% with type 2 diabetes), who enrolled in the Weight Achievement and Intensive Treatment (Why WAIT) program, a 12-week multidisciplinary ILI designed for real-world clinical practice between September 2005 and May 2018. We stratified patients based on baseline A1C into three groups: group A with A1C 9% (16.95% of participants), group B with A1C from 8 to <9% (19.15% of participants), and group C with A1C <8% (63.9% of participants). After 12 weeks of intervention, body weight decreased by 8.5±4.6 Kg in group A, 8.0±4.6 Kg in group B, and 7.6±5.8 Kg in group C (p=0.22 between groups). A1C decreased by 2.5±1.3% in group A, 1.2±0.8% in group B and 0.5±0.6% in group C (p<0.001 between groups). Pairwise comparisons of A1C changes between groups showed that: group A had 1.3% greater A1C reduction than group B (p=0.0001) and 2% greater A1C reduction than group C (p=0.0001), while group B had 0.7% greater A1C reduction than group C (p=0.0001). Conclusion: ILI may decrease A1C by up to 2.5% in patients with diabetes. In patients with a similar magnitude of weight loss, A1C reduction was more prominent in those with higher baseline A1C levels. This may be valuable for clinicians to set realistic expectations of A1C reduction for their patients in response to ILI, which is usually the primary step in diabetes management. Disclosure A.H. Eldib: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. A. Mottalib: None. S. Ashrafzadeh: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
742-P: Magnitude of A1C Improvement in Relation to Weight Loss after Intensive Lifestyle Intervention in Real-World Diabetes Practice: Thirteen Years of Observation
The effect of intensive lifestyle intervention (ILI) on A1C in real-world clinical practice is inconsistent and is frequently underestimated. It is also presumed that the magnitude of A1C improvement is solely dependent on the amount of weight loss. In this study we report the magnitude of A1C change in a large cohort of patients with diabetes who underwent ILI over 13 years in relation to their baseline A1C and the amount of weight loss. We evaluated 590 diabetic patients (age 52.5±11 years, 58.6% females, A1C 7.7±1.4%, weight 105.54±18.6 Kg, BMI 36.7±5.1 Kg/m2, diabetes duration 10.9±9.8 years, 83.7% with type 2 diabetes), who enrolled in the Weight Achievement and Intensive Treatment (Why WAIT) program, a 12-week multidisciplinary ILI designed for real-world clinical practice between September 2005 and May 2018. We stratified patients based on baseline A1C into three groups: group A with A1C 9% (16.95% of participants), group B with A1C from 8 to <9% (19.15% of participants), and group C with A1C <8% (63.9% of participants). After 12 weeks of intervention, body weight decreased by 8.5±4.6 Kg in group A, 8.0±4.6 Kg in group B, and 7.6±5.8 Kg in group C (p=0.22 between groups). A1C decreased by 2.5±1.3% in group A, 1.2±0.8% in group B and 0.5±0.6% in group C (p<0.001 between groups). Pairwise comparisons of A1C changes between groups showed that: group A had 1.3% greater A1C reduction than group B (p=0.0001) and 2% greater A1C reduction than group C (p=0.0001), while group B had 0.7% greater A1C reduction than group C (p=0.0001). Conclusion: ILI may decrease A1C by up to 2.5% in patients with diabetes. In patients with a similar magnitude of weight loss, A1C reduction was more prominent in those with higher baseline A1C levels. This may be valuable for clinicians to set realistic expectations of A1C reduction for their patients in response to ILI, which is usually the primary step in diabetes management. Disclosure A.H. Eldib: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. A. Mottalib: None. S. Ashrafzadeh: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
754-P: Full-Fat and Low-Fat Dairy, within the Same Caloric Intake, Have Similar Impact on A1C and Cardiovascular Risk Factors: A Randomized Controlled Study
The USDA Dietary Guidelines recommend consumption of 3 servings of low/non-fat dairy per day. However, the effect of higher consumption and fat content in type 2 diabetes (T2D) is unknown. This study evaluates the impact of higher consumption of full-fat (FF) and low-fat (LF) dairy on A1C and cardiovascular risk factors in patients with T2D. We enrolled 111 patients with uncontrolled T2D (age 58.5±8.9 years, 46.8% female) who were consuming 2, daily caloric intake 1925±553 kcal (43.4±7.0% carbohydrates, 37.8±5.5% total fat, 13.1±2.9% saturated fat, and 18.2±3.7% protein), LDL-C 84.3±27.4 mg/dL, TG 163.5±154.8 mg/dL, systolic BP 130±16 mmHg, and diastolic BP 71±9 mmHg. There were no differences between groups at baseline except for higher HOMA-IR in the FF group. At 6 months, % calories from saturated fat increased by 3.6% from baseline in the FF group (p<0.0001) and decreased by 1.9% in the LF group (p<0.05). The % calories from protein increased by 4.5% in the LF group (p<0.0001), but did not change in the FF group. There were no differences in total caloric intake, % calories from carbohydrates or protein, A1C, BMI, body weight, lipid parameters, or BP between the 3 groups. Conclusion: When on isocaloric diet, increasing consumption of dairy to ≥3 servings/day has similar impact on A1C, lipid profile and BP in patients with T2D, irrespective of fat content. Disclosure J. Mitri: Research Support; Spouse/Partner; AbbVie Inc., Janssen Pharmaceuticals, Inc. Research Support; Self; Kowa Pharmaceutical Europe Co. Ltd., National Dairy Council. Research Support; Spouse/Partner; Takeda Pharmaceutical Company Limited. Other Relationship; Self; National Dairy Council. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. A. Mottalib: None. V. Salsberg: None. S. Ashrafzadeh: None. T. Elseaidy: None. A. Al Maradni: None. K. Alsibai: None. A.H. Eldib: None. M. Tasabehji: None. D.M. Pober: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC. Funding National Dairy Council
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
754-P: Full-Fat and Low-Fat Dairy, within the Same Caloric Intake, Have Similar Impact on A1C and Cardiovascular Risk Factors: A Randomized Controlled Study
The USDA Dietary Guidelines recommend consumption of 3 servings of low/non-fat dairy per day. However, the effect of higher consumption and fat content in type 2 diabetes (T2D) is unknown. This study evaluates the impact of higher consumption of full-fat (FF) and low-fat (LF) dairy on A1C and cardiovascular risk factors in patients with T2D. We enrolled 111 patients with uncontrolled T2D (age 58.5±8.9 years, 46.8% female) who were consuming 2, daily caloric intake 1925±553 kcal (43.4±7.0% carbohydrates, 37.8±5.5% total fat, 13.1±2.9% saturated fat, and 18.2±3.7% protein), LDL-C 84.3±27.4 mg/dL, TG 163.5±154.8 mg/dL, systolic BP 130±16 mmHg, and diastolic BP 71±9 mmHg. There were no differences between groups at baseline except for higher HOMA-IR in the FF group. At 6 months, % calories from saturated fat increased by 3.6% from baseline in the FF group (p<0.0001) and decreased by 1.9% in the LF group (p<0.05). The % calories from protein increased by 4.5% in the LF group (p<0.0001), but did not change in the FF group. There were no differences in total caloric intake, % calories from carbohydrates or protein, A1C, BMI, body weight, lipid parameters, or BP between the 3 groups. Conclusion: When on isocaloric diet, increasing consumption of dairy to ≥3 servings/day has similar impact on A1C, lipid profile and BP in patients with T2D, irrespective of fat content. Disclosure J. Mitri: Research Support; Spouse/Partner; AbbVie Inc., Janssen Pharmaceuticals, Inc. Research Support; Self; Kowa Pharmaceutical Europe Co. Ltd., National Dairy Council. Research Support; Spouse/Partner; Takeda Pharmaceutical Company Limited. Other Relationship; Self; National Dairy Council. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. A. Mottalib: None. V. Salsberg: None. S. Ashrafzadeh: None. T. Elseaidy: None. A. Al Maradni: None. K. Alsibai: None. A.H. Eldib: None. M. Tasabehji: None. D.M. Pober: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC. Funding National Dairy Council
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
121-LB: Early Independent View of Quality of Life in Patients with Type 1 Diabetes Using Hybrid Closed-Loop Insulin Delivery System in Real-World Clinical Practice
The MiniMed™ 670G (670 HCL) is the first FDA-approved hybrid closed-loop insulin delivery system device for patients with type 1 diabetes (T1D). This study aimed at evaluating clinical and patient-reported outcomes (PROs) in patients with T1D utilizing this technology. We evaluated 54 patients with T1D using the 670 HCL in real-world clinical practice (mean age 47.9±13.2 years, 57% females, BMI 28.8±5.9 kg/m2). Data were collected at baseline and after 3 months. Measures of PROs included: Pittsburgh Sleep Quality Index (PSQI), Hypoglycemia Fear Survey Worry (HFS_W) scale, and 36-Item Short-Form Health Survey (SF-36). We also measured changes in A1C after 3 months and % of time in auto-mode (% TIAM) over the two weeks preceding the 3-month visit. Regression analyses were done between these 2 parameters and PROs. Other glycemic and quality-of-life parameters were collected at 3 months and at one year but are not included in this early report. At 3 months, A1C decreased by 0.4±0.12% from baseline (p=0.0027). Average % TIAM was 63.9±33.1%. Among all surveyed PROs, only fear of hypoglycemia and social functioning improved compared to baseline (p<0.05 for both). There was no association between changes in PROs and reduction in A1C or % TIAM. In conclusion, patients with T1D using the MiniMed™ 670G hybrid closed-loop system in real-world clinical practice are able to improve their A1C, fear of hypoglycemia, and social functioning but not other PROs included in the SF-36 after 3 months of use. The limited improvement in some of the PROs is not associated with the reduction in A1C or % TIAM. Disclosure A.H. Eldib: None. E. Toschi: Advisory Panel; Self; Lexicon Pharmaceuticals, Inc. N. Mahmoud: None. M. Tasabehji: None. S. Ashrafzadeh: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. S.E. Dhaver: None. A. Atakov-Castillo: None. A.E. Abdul-Ghani: None. K. Farkouh: None. R. Trevino: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
121-LB: Early Independent View of Quality of Life in Patients with Type 1 Diabetes Using Hybrid Closed-Loop Insulin Delivery System in Real-World Clinical Practice
The MiniMed™ 670G (670 HCL) is the first FDA-approved hybrid closed-loop insulin delivery system device for patients with type 1 diabetes (T1D). This study aimed at evaluating clinical and patient-reported outcomes (PROs) in patients with T1D utilizing this technology. We evaluated 54 patients with T1D using the 670 HCL in real-world clinical practice (mean age 47.9±13.2 years, 57% females, BMI 28.8±5.9 kg/m2). Data were collected at baseline and after 3 months. Measures of PROs included: Pittsburgh Sleep Quality Index (PSQI), Hypoglycemia Fear Survey Worry (HFS_W) scale, and 36-Item Short-Form Health Survey (SF-36). We also measured changes in A1C after 3 months and % of time in auto-mode (% TIAM) over the two weeks preceding the 3-month visit. Regression analyses were done between these 2 parameters and PROs. Other glycemic and quality-of-life parameters were collected at 3 months and at one year but are not included in this early report. At 3 months, A1C decreased by 0.4±0.12% from baseline (p=0.0027). Average % TIAM was 63.9±33.1%. Among all surveyed PROs, only fear of hypoglycemia and social functioning improved compared to baseline (p<0.05 for both). There was no association between changes in PROs and reduction in A1C or % TIAM. In conclusion, patients with T1D using the MiniMed™ 670G hybrid closed-loop system in real-world clinical practice are able to improve their A1C, fear of hypoglycemia, and social functioning but not other PROs included in the SF-36 after 3 months of use. The limited improvement in some of the PROs is not associated with the reduction in A1C or % TIAM. Disclosure A.H. Eldib: None. E. Toschi: Advisory Panel; Self; Lexicon Pharmaceuticals, Inc. N. Mahmoud: None. M. Tasabehji: None. S. Ashrafzadeh: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. S.E. Dhaver: None. A. Atakov-Castillo: None. A.E. Abdul-Ghani: None. K. Farkouh: None. R. Trevino: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
1532-P: Greater Type 2 Diabetes Risk among College Students in Egypt Is Alarming
Egypt, a country with a population of 100 million (60% of them younger than age 30 years old), is among the top 10 nations in number of patients with diabetes according to the International Diabetes Federation. Type 2 diabetes (T2D) risk among young adults in Egypt is unknown. We evaluated T2D risk among 377 college students with age ranging between 19-21 years using the Finish Diabetes Score (FDS); Female 61%, body weight 71.6±14.4 kg, BMI 25±4.5 kg/m2. The overall FDS of the entire cohort was 6 (range: 0-16). Low-risk group (LR) with FDS 2, Female 54%) compared to 48% in the greater risk group (GR) with FDS ≥7 (BMI 27.6±0.3 kg/m2, Female 68%, p<0.001, p<0.01 respectively). Among GR group, there were variable T2D risk levels; slightly elevated in 36.3%, moderately elevated in 9.8%, and highly elevated risk in 1.9%. GR group had significantly higher total cholesterol versus LR group (189±2.4 vs. 179±2.3 mg/dL, p<0.01) and higher LDL-cholesterol (115±2.2 vs. 107±2.2 mg/dL, p<0.05), while HDL-C, VLDL-C, triglycerides, fasting serum insulin, fasting plasma glucose, and HOMA-IR were not different between the 2 groups. Higher proportion of subjects in the GR group reported frequent consumption of fast food (57% vs. 45%, p<0.05). Among parameters not included in the FDS model was social stress, which was significantly higher in GR (45% vs. 35%, p<0.05), and was an independent predictor of worsening FDS (β=-1.04, P<0.01) in the total cohort. We conclude that increased T2D risk is notable among Egyptian college students, especially among females and those who are overweight. Having 48% of college students at greater T2D risk is alarming. This warrants urgent need for earlier-age screening and implementing diabetes prevention programs with specific aims of reducing body weight, improving lipid profile and reducing consumption of fast food. Social stress should be considered as an important risk factor in any future development of T2D risk model in Egypt. Disclosure E.M. Eid: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. A.H. Eldib: None. M.M. Abouelmagd: None. E.M. Fahmy: None. A.M. Elbadawy: None. H.A. Ghazi: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
1532-P: Greater Type 2 Diabetes Risk among College Students in Egypt Is Alarming
Egypt, a country with a population of 100 million (60% of them younger than age 30 years old), is among the top 10 nations in number of patients with diabetes according to the International Diabetes Federation. Type 2 diabetes (T2D) risk among young adults in Egypt is unknown. We evaluated T2D risk among 377 college students with age ranging between 19-21 years using the Finish Diabetes Score (FDS); Female 61%, body weight 71.6±14.4 kg, BMI 25±4.5 kg/m2. The overall FDS of the entire cohort was 6 (range: 0-16). Low-risk group (LR) with FDS 2, Female 54%) compared to 48% in the greater risk group (GR) with FDS ≥7 (BMI 27.6±0.3 kg/m2, Female 68%, p<0.001, p<0.01 respectively). Among GR group, there were variable T2D risk levels; slightly elevated in 36.3%, moderately elevated in 9.8%, and highly elevated risk in 1.9%. GR group had significantly higher total cholesterol versus LR group (189±2.4 vs. 179±2.3 mg/dL, p<0.01) and higher LDL-cholesterol (115±2.2 vs. 107±2.2 mg/dL, p<0.05), while HDL-C, VLDL-C, triglycerides, fasting serum insulin, fasting plasma glucose, and HOMA-IR were not different between the 2 groups. Higher proportion of subjects in the GR group reported frequent consumption of fast food (57% vs. 45%, p<0.05). Among parameters not included in the FDS model was social stress, which was significantly higher in GR (45% vs. 35%, p<0.05), and was an independent predictor of worsening FDS (β=-1.04, P<0.01) in the total cohort. We conclude that increased T2D risk is notable among Egyptian college students, especially among females and those who are overweight. Having 48% of college students at greater T2D risk is alarming. This warrants urgent need for earlier-age screening and implementing diabetes prevention programs with specific aims of reducing body weight, improving lipid profile and reducing consumption of fast food. Social stress should be considered as an important risk factor in any future development of T2D risk model in Egypt. Disclosure E.M. Eid: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. A.H. Eldib: None. M.M. Abouelmagd: None. E.M. Fahmy: None. A.M. Elbadawy: None. H.A. Ghazi: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
214-LB: Vibration-Controlled Transient Elastography Reveals Alarming Prevalence of Nonalcoholic Fatty Liver Disease and Fibrosis among Young Adults in Egypt
The spectrum of nonalcoholic fatty liver disease (NAFLD) ranges from simple fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis. The rising prevalence of NAFLD in western societies has been paralleling the obesity epidemic, however, data on young adults in countries with high obesity rates like Egypt are lacking. We evaluated 120 healthy Egyptian undergraduates (54.2% female, age range 19-22 years) using Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM) (Fibroscan®): Mean body weight was 73.3±18.1 kg, BMI 25.7±6 kg/m2, and A1C 5.1±0.24%. Variable steatosis stages were present in 47.5% of this cohort (15.8% mild, 19.2% moderate, and 12.5% severe), whereas 56.7% had fibrosis (48.35% mild, 8.35% moderate). We stratified subjects according to their BMI into 4 groups: Underweight (UW) with BMI30 kg/m2 (25.83%, mean CAP 266.9±74 dB/m, and LSM 5.3±1.4 kPa). Higher BMI values were significantly associated with higher CAP values (β=4.17, p<0.0001). Severe steatosis was significantly higher in OB group compared to other groups (29% vs. 7.14% in OW and none in NW or UW, p<0.0001). Moreover, CAP values were inversely associated with serum HDL-C (β=-1.42, p=0.001), and positively associated with serum triglycerides (TG) (β=0.33, p<0.01). In conclusion, prevalence of NAFLD among Egyptian young adults is alarmingly high with 50%< having mild or moderate fibrosis. Obesity, high serum TG and low serum HDL-C are strong predictors of severe steatosis which warrants an urgent need for intervention programs aimed at reducing body weight and improving lipid profile in this population. Disclosure S. Tomah: Stock/Shareholder; Self; Amarin Corporation. E.M. Eid: None. M.M. Abouelmagd: None. A.H. Hassan: None. A.H. Eldib: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.
- 1 June 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (Supplement)
214-LB: Vibration-Controlled Transient Elastography Reveals Alarming Prevalence of Nonalcoholic Fatty Liver Disease and Fibrosis among Young Adults in Egypt
The spectrum of nonalcoholic fatty liver disease (NAFLD) ranges from simple fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis. The rising prevalence of NAFLD in western societies has been paralleling the obesity epidemic, however, data on young adults in countries with high obesity rates like Egypt are lacking. We evaluated 120 healthy Egyptian undergraduates (54.2% female, age range 19-22 years) using Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM) (Fibroscan®): Mean body weight was 73.3±18.1 kg, BMI 25.7±6 kg/m2, and A1C 5.1±0.24%. Variable steatosis stages were present in 47.5% of this cohort (15.8% mild, 19.2% moderate, and 12.5% severe), whereas 56.7% had fibrosis (48.35% mild, 8.35% moderate). We stratified subjects according to their BMI into 4 groups: Underweight (UW) with BMI30 kg/m2 (25.83%, mean CAP 266.9±74 dB/m, and LSM 5.3±1.4 kPa). Higher BMI values were significantly associated with higher CAP values (β=4.17, p<0.0001). Severe steatosis was significantly higher in OB group compared to other groups (29% vs. 7.14% in OW and none in NW or UW, p<0.0001). Moreover, CAP values were inversely associated with serum HDL-C (β=-1.42, p=0.001), and positively associated with serum triglycerides (TG) (β=0.33, p<0.01). In conclusion, prevalence of NAFLD among Egyptian young adults is alarmingly high with 50%< having mild or moderate fibrosis. Obesity, high serum TG and low serum HDL-C are strong predictors of severe steatosis which warrants an urgent need for intervention programs aimed at reducing body weight and improving lipid profile in this population. Disclosure S. Tomah: Stock/Shareholder; Self; Amarin Corporation. E.M. Eid: None. M.M. Abouelmagd: None. A.H. Hassan: None. A.H. Eldib: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.